HPV16-miR-H1 promotes proliferation, migration, and glycolysis in head and neck squamous cell carcinoma cells via the PTEN/AKT pathway Authors: Ruilin Wang, Shangdong Li, Yuxiu Ma, Dezhuan Da, Qi Zhang, Chunyan Dang, Xuhui Zhao, Shuang Liang, Hongling Li Published: 2025 ABSTRACT Human papillomavirus type 16 (HPV16) is the most common type of infection in head and neck squamous cell carcinoma (HNSCC).The HPV16-encoded miRNA, HPV16-miR-H1, has been validated in cervical cancer tissues and cells, but its role in the pathogenesis of HNSCC remains unclear. The expression level of HPV16-miR-H1 in HNSCC cells was detected, and its mechanism of action was analyzed using bioinformatics tools and RNA sequencing. Overexpression and knockdown of HPV16-miR-H1 were performed to validate its regulatory effects on the PTEN/AKT axis and its impact on cell proliferation, migration, the cell cycle, and glycolysis. HPV16-miR-H1 was highly expressed in HPV16-positive HNSCC cells. Bioinformatics prediction and gene enrichment analysis indicated that HPV16-miR-H1 regulates PTEN transcription and the glycolysis process. Dual-luciferase reporter assays further confirmed that HPV16-miR-H1 targets the 3’-UTR region of PTEN. Functional experiments demonstrated that HPV16-miR-H1 affects HNSCC cell proliferation, migration, the cell cycle, and glycolysis. The expression of HPV16-miR-H1 in HNSCC cells was validated for the first time. Further studies revealed that it regulates the PTEN/AKT axis by targeting the 3’UTR region of PTEN, thereby enhancing the proliferation, migration, and glycolytic processes in HNSCC cells.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-31764-x. Introduction Head and neck cancer is a growing global health challenge, with 931,922 new cases and 467,125 deaths reported in 20201. Head and neck squamous cell carcinoma (HNSCC) is the most common histological type of head and neck cancer, and its development is associated with various risk factors, including tobacco, alcohol, environmental pollutants, and viral infections such as human papillomavirus (HPV) and Epstein-Barr virus (EBV)2. In recent years, HPV has been established as a major cause of the increasing incidence of a subset of HNSCCs in many regions worldwide, with HPV16 being the predominant type3. Compared to HPV-negative patients, HPV-positive HNSCC patients often present with distinct clinical characteristics, such as younger age, higher proportion of males, and non-smoking history4,5. More importantly, HPV-negative and HPV-positive HNSCC exhibit significant differences in molecular mechanisms, tumor biology, and treatment response, and are now considered distinct disease entities6. Therefore, in-depth research into the molecular mechanisms of HPV16 in HNSCC carcinogenesis is not only crucial for understanding the heterogeneity of this disease, but also holds significant importance for developing more precise and effective therapeutic strategies specifically targeting HPV16-positive HNSCC patients. The first viral-encoded miRNA was found in EBV-infected cells, and many mature viral miRNAs were subsequently identified in various viral families (herpesviruses, polyomaviruses, adenoviruses)7. EBV miRNAs can lead to the dysregulation of a variety of viral and host cellular biological processes, including viral replication, maintenance of latency, immune evasion, apoptosis and metabolism, as well as tumor proliferation and metastasis, by targeting one or more genes in both the virus and the host8. HPV16 is an envelope-less, double-stranded, circular DNA virus, and HPV infections of high-risk subtypes are associated with cervical, anogenital, and head and neck cancers9. Many studies have provided insights into the role of HPV16 in the development of HNSCC, such as viral-host gene interactions10, activation of signaling pathways11, regulation of transcription factors12, and mediation of immune escape13. Qian et al.14were the first to identify and validate HPV16-encoded miRNAs in cervical cancer cell lines and tissues; however, their mechanism of action in HNSCC remains unclear. Cancer cells typically exhibit an increased reliance on glycolysis, fulfilling the high synthetic demands required for cancer cell proliferation by enhancing glucose uptake and fermenting glucose to lactate15. The upregulation of glycolysis not only provides for the energy needs of the cell but also generates crucial metabolic intermediates necessary for the synthesis of macromolecules that support cell proliferation, invasiveness, and chemoresistance16]– [17. Existing research indicates that HPV is involved in the reprogramming of cellular metabolism, directing it towards pathways that favor rapid proliferation. The oncogenic proteins E6 and E7 promote the Warburg effect by increasing glucose uptake, activating glycolysis and the pentose phosphate pathway, elevating LDHA synthesis, and inhibiting β-oxidation18. However, the molecular mechanisms underlying abnormal aerobic glycolysis in various tumors, including HPV-positive HNSCC, remain unclear. In this study, we first validated the expression of HPV16-miR-H1 in HPV-positive HNSCC cells and its role in promoting glycolysis in these cells. Mechanistically, HPV16-miR-H1 directly targets the 3’-UTR region of PTEN, thereby regulating the PTEN/AKT axis, ultimately leading to the growth of HNSCC cells. Materials and methods Cell culture and reagents SCC4 and CAL27 are HPV-negative HNSCC cell lines (kindly provided by the laboratory of Lanzhou Heavy Ion Hospital), while UPCI-SCC-090 is an HPV16-positive HNSCC cell line (purchased from Shanghai Zhongqiao Xinzhou Biotechnology Co., Ltd.). All cell lines were authenticated by short tandem repeat analysis and tested for mycoplasma contamination. SCC4, CAL27, and human embryonic kidney cell line HEK293T were cultured in DMEM containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. UPCI-SCC-090 cells were cultured in MEM containing 10% fetal bovine serum, 100 µg/ml penicillin, and 100 µg/ml streptomycin. All cell cultures were maintained at 37 °C in a 5% CO2 humidified environment. Construction of HPV16-miR-H1 overexpression head and neck squamous cell carcinoma cell lines The pre-HPV16-miR-H1 sequence was synthesized and cloned into the pCDH-CMV-MCS-EF1-copGFP lentiviral vector. The constructed HPV16-miR-H1 expression plasmid, along with packaging plasmids, was co-transfected into HEK293T cells using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) to produce lentiviral particles. Subsequently, target cells (SCC4 and CAL27) were infected with HPV16-miR-H1 lentivirus, and stably transfected cells were selected using puromycin. Validation was performed via stem-loop RT-qPCR. Cells transfected with the empty pCDH-CMV-MCS-EF1-copGFP vector were used as controls. Transient transfection HPV16-miR-H1 inhibitor and negative control inhibitor were purchased from Genima Biotech (Shanghai, China). For the PTEN rescue experiment, the PTEN overexpression vector (pcDNA3.1-PTEN) and its control vector (pcDNA3.1 empty vector) were purchased from Hanheng Biotechnology (Shanghai, China). The small interfering RNA (siRNA) targeting PTEN and its negative control siRNA were purchased from Genima Biotech (Shanghai, China). All plasmid transfections were performed using Lipofectamine 3000 (Invitrogen, Carlsbad, California, USA) according to the manufacturer’s instructions. The synthetic RNA sequences used in this study are listed in Table S1. RT-qPCR and stem-loop RT-qPCR Total RNA was extracted using the TRIzol reagent (CW0580S, CWBIO, Beijing, China) according to the manufacturer’s instructions. For RT-qPCR analysis, cDNA was synthesized using the MonScript RTIII All-in-One Mix with dsDNase kit (MR05101, Monad, Suzhou, China), and qPCR was performed using the SYBR Green qPCR Mix (MR05101, Monad, Suzhou, China). For stem-loop RT-qPCR of miRNAs, total RNA was reverse transcribed using the miRNA First-Strand cDNA Synthesis kit (MR101-01/02, Vazyme, Nanjing, China), and qPCR was performed using the miRNA Universal SYBR qPCR Master Mix (MQ101, Vazyme, Nanjing, China). RNU6B was used as the internal control for miRNA analysis. The primer sequences used in this study are listed in Table S2. Western blotting Cells were lysed in RIPA buffer (Beyotime, China) containing a protease inhibitor cocktail (Keygen, China) and phosphatase inhibitors (Beyotime, China). Protein concentrations were estimated using a BCA assay kit (solarbio, China). Protein samples were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, USA). After blocking with 5% non-fat milk, the membranes were incubated with primary antibodies overnight at 4 °C, followed by incubation with secondary antibodies for 1 h at room temperature. Bioinformatics prediction and RNA-seq The target genes of HPV16-miR-H1 were predicted using TargetScan custom (https://www.targetscan.org/vert_40/seedmatch.html), and the binding site between HPV16-miR-H1 and PTEN was predicted using the RNA hybrid program (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/). PTEN mRNA levels were compared between HPV-negative and HPV-positive HNSCC using the online tool THInCR (The HPV-induced Cancer Resource; https://thincr.ca/). Enrichment analysis was performed using the online databases Metascape (https://metascape.org/gp/index.html) and Enrichr (https://maayanlab.cloud/Enrichr/) Total RNA was extracted using the TRIzol reagent according to the manufacturer’s instructions. RNA purity and quantification were determined using a NanoDrop2000 spectrophotometer (ThermoScientific, USA), and RNA integrity was assessed using an Agilent2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Transcriptome libraries were constructed using the VAHTS Universal V5 RNA-seq Library Prep Kit according to the manufacturer’s instructions. Transcriptome sequencing and analysis were performed by Shanghai Oebiotech Co., Ltd. (Shanghai, China). Subsequently, functional enrichment analysis of differentially expressed genes was performed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database19]– [20. Cell cycle analysis According to the cell cycle detection kit (CCS012, MultiSciences, Hangzhou, China) instructions, 1 × 106 cells were collected, resuspended in 1 ml of room temperature PBS, and then fixed overnight in -20 °C anhydrous ethanol. On the day of detection, 1 ml of DNA staining solution was added, vortexed for 5–10 s, and incubated at room temperature in the dark for 30 min. Finally, the cell cycle distribution was detected and analyzed using a flow cytometer. EdU cell proliferation assay Transfected cells (1 × 105 cells/well) were seeded in 24-well plates and cultured for 24 h. Then, 1 ml of the EdU working solution was added to each well, and the cells were incubated at 37 °C for 2.5 h. The cells were then fixed with 1 ml of 4% paraformaldehyde solution for 15 min, washed three times with 1 ml of washing buffer (P0106, Beyotime, Shanghai, China), and permeabilized with 1 ml of permeabilization buffer (P0097, Beyotime, Shanghai, China) for 10–15 min at room temperature. The EdU detection reaction was performed according to the kit instructions, followed by cell nucleus staining. Finally, the proliferation of the cells was observed under a fluorescence microscope (Olympus BX51, Japan), and the percentage of EdU-positive cells and the average fluorescence intensity were quantified using ImageJ software. Transwell migration assay Cells were cultured in serum-free medium in the upper chamber of an 8.0 μm pore size Boyden chamber (Corning Life Sciences, USA), and 700 µL of medium containing 10% FBS was added to the lower chamber. The chambers were then incubated at 37 °C with 5% CO2 for 24 h. The Transwell membrane was fixed with 4% paraformaldehyde for 25 min and stained with 0.1% crystal violet for 10 min. Photographs were taken under a microscope to evaluate the migration level of each transfected group, and the migrated cells were quantified using ImageJ software. Statistical analysis Statistical analysis was performed using SPSS 27.0 and GraphPad Prism 9.0 software. The analysis included two-sample t-tests and one-way ANOVA, with statistical significance set at P < 0.05. Single asterisks, double asterisks, and triple asterisks indicate significance levels of *P < 0.05, **P < 0.01, and ***P < 0.001, respectively. Results HPV16-miR-H1 is highly expressed in HPV16-positive HNSCC cells and targets the PTEN gene To further elucidate the role of HPV16-encoded HPV16-miR-H1, we first validated its expression in HNSCC cells. We used qRT-PCR and stem-loop qRT-PCR, respectively, to assess HPV16 E6 mRNA levels and HPV16-miR-H1 expression in HPV16-negative (SCC-4, CAL-27) and HPV16-positive (UPCI-SCC-090) cells. As expected, robust expression of both E6 and HPV16-miR-H1 was detected in the UPCI-SCC-090 cell line. Conversely, no amplification signal was detected for either target in the HPV-negative cell lines, SCC-4 and CAL-27, consistent with their known HPV status. The detailed quantification cycle (Cq) values for this analysis are provided in Table S3. TargetScan custom was used to predict the target genes of HPV16-miR-H1 (Table S4), and pathway enrichment analysis was performed using Metascape (Fig. 1A) and Enrichr (Figure S1) online databases, both of which enriched the transcriptional regulation of PTEN mRNA. Analysis using the THInCR online database revealed that the mRNA level of PTEN was lower in HPV-positive HNSCC cells compared with HPV-negative HNSCC cells (Figure S2). Consistently, Western blot analysis further confirmed that PTEN protein expression was reduced in SCC-090 cells relative to SCC4 and CAL27 cells (Fig. 1B).Based on the classical miRNA regulatory mechanism, the RNA hybridization program predicted that HPV16-miR-H1 has binding sites in the 3’-UTR region of PTEN (Fig. 1C). This was further validated by dual-luciferase reporter assays, demonstrating that the luciferase activity of the wild-type PTEN 3′-UTR construct decreased upon treatment with the HPV16-miR-H1 mimic, while the activity of the mutant PTEN 3′-UTR reporter was unaffected (Fig. 1D). RNA-seq analysis identified genes differentially regulated by HPV16-miR-H1, and KEGG enrichment analysis indicated that these genes were related to the TNF signaling pathway, cytokine-cytokine receptor interaction, human papillomavirus infection, and RIG-1-like receptor signaling pathway (Fig. 1E). Fig. 1Validation of HPV16-miR-H1 expression in HPV16-positive HNSCC cells, prediction of its targets, and enrichment analysis. (A) Pathway enrichment analysis of the predicted targets of HPV16-miR-H1 using the Metascape online database. (B) Protein levels of PTEN in SCC4, CAL27, and SCC-090 cell lines. (C) Prediction of the binding site between HPV16-miR-H1 and the 3’-UTR of PTEN using the RNA hybrid program. (D) Dual-luciferase reporter assay. HEK293T cells were co-transfected with luciferase reporter vectors containing the Wt or Mut PTEN 3’-UTR, along with the HPV16-miR-H1 mimic or negative control (NC), and luciferase activity was measured 48 h after transfection. (E) KEGG pathway enrichment analysis of differentially expressed genes using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database19,20. The plot shows the most significantly enriched pathways in SCC4 and CAL27 cells following HPV16-miR-H1 overexpression. Validation of HPV16-miR-H1 expression in HPV16-positive HNSCC cells, prediction of its targets, and enrichment analysis. (A) Pathway enrichment analysis of the predicted targets of HPV16-miR-H1 using the Metascape online database. (B) Protein levels of PTEN in SCC4, CAL27, and SCC-090 cell lines. (C) Prediction of the binding site between HPV16-miR-H1 and the 3’-UTR of PTEN using the RNA hybrid program. (D) Dual-luciferase reporter assay. HEK293T cells were co-transfected with luciferase reporter vectors containing the Wt or Mut PTEN 3’-UTR, along with the HPV16-miR-H1 mimic or negative control (NC), and luciferase activity was measured 48 h after transfection. (E) KEGG pathway enrichment analysis of differentially expressed genes using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database19,20. The plot shows the most significantly enriched pathways in SCC4 and CAL27 cells following HPV16-miR-H1 overexpression. HPV16-miR-H1 enhances HNSCC cell proliferation and migration by downregulating PTEN and upregulating phosphorylated AKT To investigate the regulatory role of HPV16-miR-H1 in the PTEN/AKT signaling pathway and its effects on cell cycle, proliferation, and migration in HNSCC cells, HPV16-miR-H1 was transfected into SCC4 and CAL27 cells to generate SCC4-HPV16-miR-H1 and CAL27-HPV16-miR-H1 cell lines. Transfection efficiency was verified by stem-loop real-time RT-PCR. The results showed that ectopic expression of HPV16-miR-H1 in SCC4 cells significantly decreased PTEN mRNA (Fig. 2A) and protein levels, accompanied by increased p-AKT protein expression(Fig. 2B). Compared with the negative control group, HPV16-miR-H1 overexpression markedly reduced the proportion of cells in the G0/G1 and G2/M phases, while increasing the proportion of cells in the S phase (Fig. 2E). Consistently, cell proliferation (Fig. 2C) and migration (Fig. 2D) were significantly enhanced. Similarly, in CAL27 cells, ectopic expression of HPV16-miR-H1 also led to downregulation of PTEN mRNA (Fig. 2F) and protein, upregulation of p-AKT protein(Fig. 2G), an increased proportion of S-phase cells (Fig. 2J), as well as significantly promoted proliferation (Fig. 2H) and migration (Fig. 2I). Fig. 2HPV16-miR-H1 enhances HNSCC cell proliferation and migration by downregulating PTEN and upregulating phosphorylated AKT. (A) RT-qPCR verification of PTEN mRNA levels in SCC4 cells ectopically expressing HPV16-miR-H1. (B) Western blot analysis of PTEN and p-AKT protein levels in SCC4 cells ectopically expressing HPV16-miR-H1. (C) EdU assay to assess the proliferation of SCC4 cells ectopically expressing HPV16-miR-H1. (D) Transwell migration assay to evaluate the effect of HPV16-miR-H1 on the migration of SCC4 cells. (E) PI staining to assess the effect of HPV16-miR-H1 on the cell cycle of SCC4 cells. (F) RT-qPCR verification of PTEN mRNA levels in CAL27 cells ectopically expressing HPV16-miR-H1. (G) Western blot analysis of PTEN and p-AKT protein levels in CAL27 cells ectopically expressing HPV16-miR-H1. EdU assay (H), Transwell migration assay (I), and PI staining (J) were performed using CAL27 cells ectopically expressing HPV16-miR-H1 to detect changes in cell proliferation, migration, and cell cycle, respectively. HPV16-miR-H1 enhances HNSCC cell proliferation and migration by downregulating PTEN and upregulating phosphorylated AKT. (A) RT-qPCR verification of PTEN mRNA levels in SCC4 cells ectopically expressing HPV16-miR-H1. (B) Western blot analysis of PTEN and p-AKT protein levels in SCC4 cells ectopically expressing HPV16-miR-H1. (C) EdU assay to assess the proliferation of SCC4 cells ectopically expressing HPV16-miR-H1. (D) Transwell migration assay to evaluate the effect of HPV16-miR-H1 on the migration of SCC4 cells. (E) PI staining to assess the effect of HPV16-miR-H1 on the cell cycle of SCC4 cells. (F) RT-qPCR verification of PTEN mRNA levels in CAL27 cells ectopically expressing HPV16-miR-H1. (G) Western blot analysis of PTEN and p-AKT protein levels in CAL27 cells ectopically expressing HPV16-miR-H1. EdU assay (H), Transwell migration assay (I), and PI staining (J) were performed using CAL27 cells ectopically expressing HPV16-miR-H1 to detect changes in cell proliferation, migration, and cell cycle, respectively. Inhibition of HPV16-miR-H1 downregulates phosphorylated AKT and suppresses HNSCC cell proliferation and migration by increasing PTEN levels Conversely, downregulating HPV16-miR-H1 in SCC4-HPV16-miR-H1 cells using an HPV16-miR-H1 inhibitor increased PTEN mRNA (Fig. 3A) and protein levels, downregulated p-AKT levels (Fig. 3B), and reduced the proportion of cells in S phase (Fig. 3E), cell proliferation (Fig. 3C), and migration (Fig. 3D). Similarly, inhibiting HPV16-miR-H1 in UPCI-SCC-090 cells resulted in upregulated PTEN mRNA (Fig. 3F) and protein levels(Fig. 3G), a decreased proportion of cells in S phase (Fig. 3J), reduced cell proliferation (Fig. 3H), and decreased migration (Fig. 3I). Furthermore, we obtained consistent results in inhibitor-treated CAL27-HPV16-miR-H1 cells, as evidenced by increased PTEN expression and reduced cell proliferation and migration (Supplementary Fig. 4).These results indicate that HPV16-miR-H1 promotes the proliferation and migration of HNSCC cells by regulating the PTEN/AKT axis. Fig. 3Inhibition of HPV16-miR-H1 reduces HNSCC cell proliferation and migration by increasing PTEN and decreasing phosphorylated AKT. (A) RT-qPCR verification of PTEN mRNA levels in SCC4-HPV16-miR-H1 cells with HPV16-miR-H1 inhibition. (B) Western blot analysis of PTEN and p-AKT protein levels in SCC4-HPV16-miR-H1 cells with HPV16-miR-H1 inhibition. (C) EdU assay to assess the proliferation of SCC4-HPV16-miR-H1 cells with HPV16-miR-H1 inhibition. (D) Transwell migration assay to evaluate the effect of HPV16-miR-H1 inhibition on the migration of SCC4-HPV16-miR-H1 cells. (E) PI staining to assess the effect of HPV16-miR-H1 inhibition on the cell cycle of SCC4-HPV16-miR-H1 cells. (F) RT-qPCR verification of PTEN mRNA levels in SCC-090 cells with HPV16-miR-H1 inhibition. (G) Western blot analysis of PTEN and p-AKT protein levels in SCC-090 cells with HPV16-miR-H1 inhibition. EdU assay (H), Transwell migration assay (I), and PI staining (J) were performed using SCC-090 cells with HPV16-miR-H1 inhibition to detect changes in cell proliferation, migration, and cell cycle, respectively. Inhibition of HPV16-miR-H1 reduces HNSCC cell proliferation and migration by increasing PTEN and decreasing phosphorylated AKT. (A) RT-qPCR verification of PTEN mRNA levels in SCC4-HPV16-miR-H1 cells with HPV16-miR-H1 inhibition. (B) Western blot analysis of PTEN and p-AKT protein levels in SCC4-HPV16-miR-H1 cells with HPV16-miR-H1 inhibition. (C) EdU assay to assess the proliferation of SCC4-HPV16-miR-H1 cells with HPV16-miR-H1 inhibition. (D) Transwell migration assay to evaluate the effect of HPV16-miR-H1 inhibition on the migration of SCC4-HPV16-miR-H1 cells. (E) PI staining to assess the effect of HPV16-miR-H1 inhibition on the cell cycle of SCC4-HPV16-miR-H1 cells. (F) RT-qPCR verification of PTEN mRNA levels in SCC-090 cells with HPV16-miR-H1 inhibition. (G) Western blot analysis of PTEN and p-AKT protein levels in SCC-090 cells with HPV16-miR-H1 inhibition. EdU assay (H), Transwell migration assay (I), and PI staining (J) were performed using SCC-090 cells with HPV16-miR-H1 inhibition to detect changes in cell proliferation, migration, and cell cycle, respectively. HPV16-miR-H1 enhances glycolysis in HNSCC cells Based on the RNA-seq results, Enrichr enrichment analysis revealed a significant enrichment of Pyruvaldehyde (a byproduct of glycolysis) (Figure S3). To validate the role of HPV16-miR-H1 in glucose metabolism in HNSCC, changes in intracellular glucose and lactate concentrations were further examined. The results showed that, compared to cells transfected with a negative control, ectopic expression of HPV16-miR-H1 in SCC4 and CAL27 cells led to a decrease in intracellular glucose concentration and an increase in lactate concentration. Conversely, downregulation of HPV16-miR-H1 in SCC4-HPV16-miR-H1 and SCC-090 cells led to opposite changes (Fig. 4A-D). This suggests that HPV16-miR-H1 may influence the expression of glucose metabolism-related genes by regulating the glycolysis pathway. GLUT1, HK2, PDK1, and LDHA are core enzymes catalyzing key steps in the glycolysis pathway. Experimental results demonstrated that HPV16-miR-H1 significantly upregulated the mRNA and protein levels of GLUT1, HK2, PDK1, and LDHA, while downregulation of HPV16-miR-H1 reduced the mRNA and protein levels of these enzymes (Fig. 4E-I). Fig. 4HPV16-miR-H1 enhances glycolysis in HNSCC cells. (A) Detection of intracellular glucose levels in SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells. (B) Detection of intracellular lactate levels in SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells. (C) Detection of intracellular glucose levels in CAL27-HPV16-miR-H1 and SCC-090-In-HPV16-miR-H1 cells. (D) Detection of intracellular lactate levels in CAL27-HPV16-miR-H1 and SCC-090-In-HPV16-miR-H1 cells. (E) RT-qPCR analysis of mRNA levels of GLUT1, (F) HK2, (G) PDK1, and (H) LDHA in stable expression of SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells. (I) Measurement of protein levels of GLUT1, HK2, PDK1, and LDHA in SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells by Western blotting. HPV16-miR-H1 enhances glycolysis in HNSCC cells. (A) Detection of intracellular glucose levels in SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells. (B) Detection of intracellular lactate levels in SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells. (C) Detection of intracellular glucose levels in CAL27-HPV16-miR-H1 and SCC-090-In-HPV16-miR-H1 cells. (D) Detection of intracellular lactate levels in CAL27-HPV16-miR-H1 and SCC-090-In-HPV16-miR-H1 cells. (E) RT-qPCR analysis of mRNA levels of GLUT1, (F) HK2, (G) PDK1, and (H) LDHA in stable expression of SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells. (I) Measurement of protein levels of GLUT1, HK2, PDK1, and LDHA in SCC4-HPV16-miR-H1 and SCC4-In-HPV16-miR-H1 cells by Western blotting. Overexpression of PTEN can reverse the phenotype induced by HPV16-miR-H1 To verify the causal relationship between PTEN downregulation and the tumor-promoting effects of HPV16-miR-H1 in HNSCC cells and the glycolytic process, we examined the effects of PTEN overexpression on the proliferation, migration, and cell cycle of SCC4-HPV16-miR-H1 cells. Compared to the negative control group, overexpression of PTEN in SCC4-HPV16-miR-H1 cells (Fig. 5A) reduced the levels of p-AKT (Fig. 5B). Additionally, PTEN overexpression reduced the proportion of S-phase cells in SCC4-HPV16-miR-H1 and significantly suppressed cell proliferation and migration (Fig. 5C-E). PTEN overexpression partially reversed the effects of HPV16-miR-H1 on glucose and lactate concentrations in HNSCC cells (Fig. 5F-G), and further analysis of the protein levels of GLUT1, HK2, PDK1, and LDHA yielded similar results (Fig. 5H). This indicates that restoring PTEN can counteract the effects of HPV16-miR-H1 on the proliferation, migration, and glycolysis of HNSCC cells. Fig. 5Overexpression of PTEN reverses the phenotypes induced by HPV16-miR-H1. (A) RT-qPCR verification of PTEN mRNA levels in SCC4-HPV16-miR-H1 cells with PTEN overexpression. (B) Western blot analysis of PTEN protein levels and p-AKT protein levels in SCC4-HPV16-miR-H1 cells with PTEN overexpression. (C) EdU assay to assess the proliferation of SCC4-HPV16-miR-H1 cells with PTEN overexpression. (D) Transwell migration assay to evaluate the effect of PTEN overexpression on the migration of SCC4-HPV16-miR-H1 cells. (E) PI staining to assess the effect of PTEN overexpression on the cell cycle of SCC4-HPV16-miR-H1 cells. Assessment of intracellular glucose (F) and lactate (G) level changes in SCC4-HPV16-miR-H1 cells overexpressing PTEN using assay kits. (H) Western blot analysis of the protein levels of GLUT1, HK2, PDK1, and LDHA in SCC4-HPV16-miR-H1 cells with PTEN overexpression. Overexpression of PTEN reverses the phenotypes induced by HPV16-miR-H1. (A) RT-qPCR verification of PTEN mRNA levels in SCC4-HPV16-miR-H1 cells with PTEN overexpression. (B) Western blot analysis of PTEN protein levels and p-AKT protein levels in SCC4-HPV16-miR-H1 cells with PTEN overexpression. (C) EdU assay to assess the proliferation of SCC4-HPV16-miR-H1 cells with PTEN overexpression. (D) Transwell migration assay to evaluate the effect of PTEN overexpression on the migration of SCC4-HPV16-miR-H1 cells. (E) PI staining to assess the effect of PTEN overexpression on the cell cycle of SCC4-HPV16-miR-H1 cells. Assessment of intracellular glucose (F) and lactate (G) level changes in SCC4-HPV16-miR-H1 cells overexpressing PTEN using assay kits. (H) Western blot analysis of the protein levels of GLUT1, HK2, PDK1, and LDHA in SCC4-HPV16-miR-H1 cells with PTEN overexpression. Downregulation of PTEN leads to phenotypes similar to HPV16-miR-H1 To investigate whether downregulation of PTEN would also lead to phenotypes similar to those induced by HPV16-miR-H1, we transfected siPTEN into SCC4 cells (SCC4-siPTEN). Transfection of siPTEN effectively reduced PTEN mRNA (Fig. 6A) and protein expression while increasing the protein levels of p-AKT(Fig. 6B). Compared to cells transfected with control siRNA, SCC4-siPTEN cells demonstrated an increased percentage of cells in S phase, along with enhanced proliferation and migration capabilities (Fig. 6C-E). Analyzing the effects of PTEN downregulation on glycolysis in SCC4 cells revealed increased intracellular glucose levels and decreased intracellular lactate levels in SCC4-siPTEN cells (Fig. 6F-G), along with upregulated protein levels of GLUT1, HK2, PDK1, and LDHA (Fig. 6H). Fig. 6Knockdown of PTEN induces phenotypes similar to those of HPV16-miR-H1. (A) RT-qPCR verification of PTEN mRNA levels in SCC4 cells with PTEN knockdown. (B) Western blot analysis of PTEN protein levels and p-AKT protein levels in SCC4 cells with PTEN knockdown. (C) EdU assay to assess the proliferation of SCC4 cells with PTEN knockdown. (D) Transwell migration assay to evaluate the effect of PTEN knockdown on the migration of SCC4 cells. (E) PI staining to assess the effect of PTEN knockdown on the cell cycle of SCC4 cells. Assessment of changes in intracellular glucose (F) and lactate (G) levels in SCC4 cells with PTEN knockdown, using assay kits. (H) Western blot analysis of the protein levels of GLUT1, HK2, PDK1, and LDHA in SCC4 cells with PTEN knockdown. Knockdown of PTEN induces phenotypes similar to those of HPV16-miR-H1. (A) RT-qPCR verification of PTEN mRNA levels in SCC4 cells with PTEN knockdown. (B) Western blot analysis of PTEN protein levels and p-AKT protein levels in SCC4 cells with PTEN knockdown. (C) EdU assay to assess the proliferation of SCC4 cells with PTEN knockdown. (D) Transwell migration assay to evaluate the effect of PTEN knockdown on the migration of SCC4 cells. (E) PI staining to assess the effect of PTEN knockdown on the cell cycle of SCC4 cells. Assessment of changes in intracellular glucose (F) and lactate (G) levels in SCC4 cells with PTEN knockdown, using assay kits. (H) Western blot analysis of the protein levels of GLUT1, HK2, PDK1, and LDHA in SCC4 cells with PTEN knockdown. Knockdown of PTEN in SCC4-HPV16-miR-H1 cells can counteract the effects of HPV16-miR-H1 inhibitor Next, we further investigated the roles of HPV16-miR-H1 and PTEN in SCC4-HPV16-miR-H1 cells. The results showed that inhibition of HPV16‑miR‑H1 upregulated PTEN expression, whereas this upregulation was reversed when PTEN was simultaneously knocked down (Fig. 7A). Inhibition of HPV16‑miR‑H1 also downregulated p‑AKT expression, and this downregulation was similarly reversed upon PTEN knockdown (Fig. 7B).Knockdown of PTEN reversed the antitumor effects of the HPV16-miR-H1 inhibitor, leading to an increased proportion of SCC4-HPV16-miR-H1 cells in S phase and enhanced proliferation and migration (Fig. 7F-H). Similarly, knockdown of PTEN reversed the inhibitory effects of the HPV16-miR-H1 inhibitor on glycolysis (Fig. 7C-E). In summary, these results indicate that downregulation of PTEN also leads to phenotypes similar to those induced by HPV16-miR-H1. Fig. 7Knockdown of PTEN in SCC4-HPV16-miR-H1 cells can counteract the effects of the HPV16-miR-H1 inhibitor. (A-B) Protein levels of PTEN and p-AKT in SCC4-HPV16-miR-H1 cells were measured by Western blotting after co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or their corresponding negative controls. Changes in intracellular glucose (C) and lactate (D) levels in SCC4-HPV16-miR-H1 cells were determined by kit after co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or their corresponding negative controls. (E) Protein levels of GLUT1, HK2, PDK1 and LDHA were determined by protein blotting after co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or their corresponding negative controls. EdU assay (F), transwell migration (G) and PI staining assay (H) for co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or its corresponding negative control followed by alterations in cell proliferation, migration ability and cell cycle. Knockdown of PTEN in SCC4-HPV16-miR-H1 cells can counteract the effects of the HPV16-miR-H1 inhibitor. (A-B) Protein levels of PTEN and p-AKT in SCC4-HPV16-miR-H1 cells were measured by Western blotting after co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or their corresponding negative controls. Changes in intracellular glucose (C) and lactate (D) levels in SCC4-HPV16-miR-H1 cells were determined by kit after co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or their corresponding negative controls. (E) Protein levels of GLUT1, HK2, PDK1 and LDHA were determined by protein blotting after co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or their corresponding negative controls. EdU assay (F), transwell migration (G) and PI staining assay (H) for co-transfection of HPV16-miR-H1 inhibitor and PTEN siRNA or its corresponding negative control followed by alterations in cell proliferation, migration ability and cell cycle. Discussion In this study, we verified for the first time the expression of HPV16-miR-H1, which is encoded by HPV16 itself, in HPV16-positive HNSCC cells, and further demonstrated that HPV16-miR-H1 regulates the PTEN/AKT axis by directly targeting the 3′-UTR of PTEN, thus enhancing the proliferation, migration ability and glycolysis of HNSCC cells. This study provides new evidence for the notion that HPV16 itself can encode miRNAs, however, the lack of relevant studies also emphasizes the need for further research on the function of HPV16-encoded miRNAs, especially in the field of HNSCC. Despite the large number (more than 225) of viral miRNAs that have been identified, there is still a lack of in-depth functional understanding of the miRNAs encoded by most viruses7. Since EBV was described as the first human oncolytic virus to encode miRNAs, a large number of studies have demonstrated that these molecules interact with both viral and host targets to regulate biological processes critical for oncogenesis and promote cellular transformation and tumor progression in EBV-associated cancers21. Based on the fact that HPV has a dsDNA genome, replicates predominantly in the nucleus, and has the ability to establish persistent infections and latency, and considering the possibility that it has its own encoded miRNAs, several studies predicted that HPV encodes its own miRNAs22–24, which were further validated in HPV-positive cervical cancer cells and tissues25. A recent study showed that HPV16-miR-H1 and HPV16-miR-H6 were highly expressed in both SiHa cells (HPV16-positive) and tissue samples from HPV16-positive cervical cancer patients, and that they regulate the expression of key genes by modulating enhancer activity, which may improve the migration of SiHa cells26, but few studies have investigated their role in HNSCC. HPV carcinogenesis is primarily driven by two viral early genes (E6 and E7, commonly referred to as HPV oncogenes), which physiologically function to trigger the entry of the epithelial basal lamina into the cell cycle, thereby permitting the replication of the viral genome27. PI3K/AKT/mTOR pathway aberrant activation frequently occurs in HPV-positive HNSCC28.Activation of this pathway by HPV E6, E7, and E5 is critical for several key steps in the viral lifecycle, including viral host-cell entry, inhibition of autophagy to establish infection29, viral replication30, and resistance to T cell mediated apoptosis31. PTEN is a lipid phosphatase and a key negative regulator of the PI3K/AKT signaling pathway, whose loss or downregulation has been observed in approximately 30% of HNSCC cases32. Loss of PTEN promotes cancer progression by enhancing glucose metabolism. In prostate cancer cells, PTEN loss is associated with increased pAKT expression and upregulated glucose metabolism, contributing to tumor cell survival33. Consistently, we observed that PTEN downregulation enhances glycolysis in HPV-positive HNSCC cells. Metabolic reprogramming, an important hallmark of cancer progression, consumes more glucose and converts pyruvate to lactate even in a normoxic state, which is known as the Warburg effect34. Accelerated energy supply through aerobic glycolysis contributes to the proliferation of cancer cells, and the acidic microenvironment formed by the accumulation of lactic acid also favors cancer invasion and metastasis35. Analysis of the metabolic profiles of HPV-negative and HPV-positive HNSCC cell lines revealed that HPV-positive cell lines had a higher rate of basal glycolysis, whereas HPV-negative HNSCC cells exhibited a more diverse metabolism36.E6 and E7 may disrupt glycolysis in HPV-positive cervical cancer cells37]– [38, which may explain the increased expression of glycolytic genes in HPV-positive HNSCC increased expression of glycolytic genes in HNSCC39. However, another study demonstrated the opposite results, with higher rates of glycolysis and glycolytic capacity in HPV-negative HNSCC cell lines40. This indicates that further investigation into the mechanisms by which HPV influences glycolysis in HNSCC is still required. Our study demonstrates that HPV16-miR-H1 downregulates PTEN expression in HPV-positive HNSCC cells, thereby promoting cell proliferation and migration. However, this mechanism alone does not seem sufficient to explain why HPV-positive HNSCC patients generally have a better prognosis.On the one hand, although HPV-positive HNSCC patients tend to have a more favorable prognosis overall, a subset of these patients still experience recurrence and/or metastasis, which is associated with poor clinical outcomes41. HNSCC is a highly heterogeneous malignancy, and its clinical behavior is influenced by various factors, including tumor location, genetic background, and the tumor microenvironment42. Therefore, our findings may provide new insights into the potential molecular mechanisms underlying poor prognosis in certain HPV-positive HNSCC patients.On the other hand, previous studies have reported that HPV16 E6 and E7 oncoproteins can suppress PTEN expression. However, PTEN expression has been found to be upregulated in tissue samples from HPV-positive HNSCC patients43. This suggests that HPV-mediated regulation of PTEN may involve a more complex and multilayered regulatory network, encompassing transcriptional, post-transcriptional, and protein-level mechanisms. Thus, current research has yet to fully elucidate the mechanisms underlying the favorable prognosis of HPV-positive HNSCC patients, and further studies are required to identify the key regulatory factors involved. Fig. 8Mechanism hypothesis diagram of this study. In the nucleus, the primary transcript pri-HPV16-miR-H1 is first recognized and cleaved by the core components of the Microprocessor complex, Drosha and DiGeorge Syndrome Critical Region 8 (DGCR8), generating the precursor molecule pre-HPV16-miR-H1. Subsequently, pre-HPV16-miR-H1 is transported to the cytoplasm via Exportin-5, a nuclear export protein. In the cytoplasm, pre-HPV16-miR-H1 is further processed by the RNAse III enzyme Dicer, producing the mature HPV16-miR-H1. HPV16-miR-H1 directly binds to the 3’-UTR of the tumor suppressor gene PTEN mRNA, reducing PTEN protein levels. As a result, the phosphorylation level of AKT (p-AKT) increases, promoting glycolysis, proliferation, and migration of HNSCC cells, ultimately accelerating tumor progression. Mechanism hypothesis diagram of this study. In the nucleus, the primary transcript pri-HPV16-miR-H1 is first recognized and cleaved by the core components of the Microprocessor complex, Drosha and DiGeorge Syndrome Critical Region 8 (DGCR8), generating the precursor molecule pre-HPV16-miR-H1. Subsequently, pre-HPV16-miR-H1 is transported to the cytoplasm via Exportin-5, a nuclear export protein. In the cytoplasm, pre-HPV16-miR-H1 is further processed by the RNAse III enzyme Dicer, producing the mature HPV16-miR-H1. HPV16-miR-H1 directly binds to the 3’-UTR of the tumor suppressor gene PTEN mRNA, reducing PTEN protein levels. As a result, the phosphorylation level of AKT (p-AKT) increases, promoting glycolysis, proliferation, and migration of HNSCC cells, ultimately accelerating tumor progression. This study has certain limitations. First, the expression of other HPV16-encoded miRNAs (including HPV16-miR-H2, HPV16-miR-H3, HPV16-miR-H5, and HPV16-miR-H6) has not yet been validated in HPV16-positive HNSCC cells. Second, the expression of HPV16-miR-H1 in tissue samples has not been confirmed, and its regulatory mechanisms in vivo remain to be explored. Further research is essential to comprehensively elucidate the role of HPV16-encoded miRNAs in HNSCC and their potential molecular mechanisms. Based on our findings, we have constructed a model diagram (Fig. 8) to illustrate the potential mechanisms of HPV16-miR-H1 in HNSCC. Conclusion Our data first validated the expression of the HPV16-encoded HPV16-miR-H1 in HPV16-positive HNSCC cells, and further studies revealed that it regulates the PTEN/AKT axis by directly targeting the 3’-UTR of PTEN mRNA, thereby enhancing the proliferation, migration, and glycolysis of HNSCC cells. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1